Acorda Therapeutics Inc (ACORQ)
0.85
+0.15
(+21.43%)
USD |
OTCM |
May 21, 16:00
Acorda Therapeutics Net Income (Quarterly): -27.40M for March 31, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -27.40M |
| December 31, 2023 | -217.76M |
| September 30, 2023 | -8.888M |
| June 30, 2023 | -9.381M |
| March 31, 2023 | -16.82M |
| December 31, 2022 | 19.14M |
| September 30, 2022 | -13.85M |
| June 30, 2022 | -46.68M |
| March 31, 2022 | -24.52M |
| December 31, 2021 | -20.57M |
| September 30, 2021 | -27.07M |
| June 30, 2021 | -22.86M |
| March 31, 2021 | -33.45M |
| December 31, 2020 | -83.05M |
| September 30, 2020 | 7.347M |
| June 30, 2020 | -17.42M |
| March 31, 2020 | -6.472M |
| December 31, 2019 | 65.66M |
| September 30, 2019 | -263.54M |
| June 30, 2019 | -27.49M |
| March 31, 2019 | -47.60M |
| December 31, 2018 | 9.595M |
| September 30, 2018 | -13.91M |
| June 30, 2018 | 46.20M |
| March 31, 2018 | -8.199M |
| Date | Value |
|---|---|
| December 31, 2017 | -170.08M |
| September 30, 2017 | -25.20M |
| June 30, 2017 | -8.196M |
| March 31, 2017 | -18.90M |
| December 31, 2016 | -3.094M |
| September 30, 2016 | -12.72M |
| June 30, 2016 | -18.28M |
| March 31, 2016 | -0.52M |
| December 31, 2015 | 9.205M |
| September 30, 2015 | 3.941M |
| June 30, 2015 | 0.997M |
| March 31, 2015 | -3.085M |
| December 31, 2014 | 0.33M |
| September 30, 2014 | 11.95M |
| June 30, 2014 | 4.685M |
| March 31, 2014 | 0.703M |
| December 31, 2013 | 6.191M |
| September 30, 2013 | 7.477M |
| June 30, 2013 | 3.91M |
| March 31, 2013 | -1.139M |
| December 31, 2012 | 132.97M |
| September 30, 2012 | 9.594M |
| June 30, 2012 | 4.545M |
| March 31, 2012 | 7.846M |
| December 31, 2011 | 12.69M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-263.54M
Minimum
Sep 2019
65.66M
Maximum
Dec 2019
-38.75M
Average
-21.72M
Median
Net Income (Quarterly) Benchmarks
| BioSig Technologies Inc | -6.049M |
| Verve Therapeutics Inc | -48.74M |
| Spectral AI Inc | -10.63M |
| AIM ImmunoTech Inc | -5.817M |
| Protalix BioTherapeutics Inc | -4.595M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 20.29M |
| Total Expenses (Quarterly) | 33.68M |
| EPS Diluted (Quarterly) | -22.06 |
| Enterprise Value | 183.17M |
| Gross Profit Margin (Quarterly) | 81.73% |
| Profit Margin (Quarterly) | -135.0% |
| Earnings Yield | -24.95K% |
| Normalized Earnings Yield | -4855.46 |